Literature DB >> 20496886

Uptake of pramipexole by human organic cation transporters.

Lei Diao1, Yan Shu, James E Polli.   

Abstract

Pramipexole is a hydrophilic, weakly basic drug, but exhibits high oral bioavailability in humans (>90%). In rats, rOct1 and rOct2 contribute toward pramipexole excretion into urine. The objective of this study was to assess whether pramipexole is a substrate for human OCT1-3. In vitro uptake studies were performed using hOCT1-MDCK monolayers, hOCT2-HEK cells and hOCT3-HEK cells. hOCT2 transported pramipexole in a high affinity manner (K(t) = 15.4 +/- 4.1 microM, J(max) = 0.476 +/- 0.028 pmol/s/cm(2)). hOCT3 transported pramipexole in a low affinity manner (K(t) = 138 +/- 31 microM, J(max) = 1.10 +/- 0.08 pmol/s/cm(2)). Although previously reported to be translocated by rOct1, pramipexole was not a substrate for hOCT1. The human intestinal absorption of pramipexole may involve transport by OCT3 and possibly OCT2. OCT2- and OCT3-mediated transport of pramipexole have implications in the drug's elimination from the kidney and distribution in the brain, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20496886      PMCID: PMC2914150          DOI: 10.1021/mp100036b

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  23 in total

1.  Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.

Authors:  D Gründemann; B Schechinger; G A Rappold; E Schömig
Journal:  Nat Neurosci       Date:  1998-09       Impact factor: 24.884

2.  The localisation of the extraneuronal monoamine transporter (EMT) in rat brain.

Authors:  Christine Haag; Reinhard Berkels; Dirk Gründemann; Andreas Lazar; Dirk Taubert; Edgar Schömig
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

3.  Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.

Authors:  C E Wright; T L Sisson; A K Ichhpurani; G R Peters
Journal:  J Clin Pharmacol       Date:  1997-06       Impact factor: 3.126

4.  Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1).

Authors:  M J Dresser; A T Gray; K M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

5.  Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract.

Authors:  Tomohiro Terada; Yutaka Shimada; Xiaoyue Pan; Koshiro Kishimoto; Takaki Sakurai; Ryuichiro Doi; Hisashi Onodera; Toshiya Katsura; Masayuki Imamura; Ken-ichi Inui
Journal:  Biochem Pharmacol       Date:  2005-11-02       Impact factor: 5.858

6.  Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.

Authors:  Peter Jenner; Michael Könen-Bergmann; Cornelia Schepers; Sebastian Haertter
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393

7.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.

Authors:  Yan Shu; Maya K Leabman; Bo Feng; Lara M Mangravite; Conrad C Huang; Doug Stryke; Michiko Kawamoto; Susan J Johns; Joseph DeYoung; Elaine Carlson; Thomas E Ferrin; Ira Herskowitz; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

8.  Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.

Authors:  Naoki Ishiguro; Asami Saito; Kazutoshi Yokoyama; Makoto Morikawa; Takashi Igarashi; Ikumi Tamai
Journal:  Drug Metab Dispos       Date:  2005-01-07       Impact factor: 3.922

9.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

10.  Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation.

Authors:  Vincent Vialou; Anne Amphoux; Ronald Zwart; Bruno Giros; Sophie Gautron
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

View more
  2 in total

1.  Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.

Authors:  Obinna N Obianom; Ana L Coutinho; Wei Yang; Hong Yang; Fengtian Xue; Yan Shu
Journal:  Mol Pharm       Date:  2017-07-21       Impact factor: 4.939

Review 2.  Mechanisms of peripheral levodopa resistance in Parkinson's disease.

Authors:  Milan Beckers; Bastiaan R Bloem; Marcel M Verbeek
Journal:  NPJ Parkinsons Dis       Date:  2022-05-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.